These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
253 related articles for article (PubMed ID: 24352648)
1. Molecular pathways: response and resistance to BRAF and MEK inhibitors in BRAF(V600E) tumors. Das Thakur M; Stuart DD Clin Cancer Res; 2014 Mar; 20(5):1074-80. PubMed ID: 24352648 [TBL] [Abstract][Full Text] [Related]
2. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Morris EJ; Jha S; Restaino CR; Dayananth P; Zhu H; Cooper A; Carr D; Deng Y; Jin W; Black S; Long B; Liu J; Dinunzio E; Windsor W; Zhang R; Zhao S; Angagaw MH; Pinheiro EM; Desai J; Xiao L; Shipps G; Hruza A; Wang J; Kelly J; Paliwal S; Gao X; Babu BS; Zhu L; Daublain P; Zhang L; Lutterbach BA; Pelletier MR; Philippar U; Siliphaivanh P; Witter D; Kirschmeier P; Bishop WR; Hicklin D; Gilliland DG; Jayaraman L; Zawel L; Fawell S; Samatar AA Cancer Discov; 2013 Jul; 3(7):742-50. PubMed ID: 23614898 [TBL] [Abstract][Full Text] [Related]
3. BRAF inhibitors in cancer therapy. Hertzman Johansson C; Egyhazi Brage S Pharmacol Ther; 2014 May; 142(2):176-82. PubMed ID: 24325952 [TBL] [Abstract][Full Text] [Related]
8. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863 [TBL] [Abstract][Full Text] [Related]
9. Activities of multiple cancer-related pathways are associated with BRAF mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells. Liu D; Liu X; Xing M Cell Cycle; 2014; 13(2):208-19. PubMed ID: 24200969 [TBL] [Abstract][Full Text] [Related]
11. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. Liu D; Hu S; Hou P; Jiang D; Condouris S; Xing M Clin Cancer Res; 2007 Feb; 13(4):1341-9. PubMed ID: 17317846 [TBL] [Abstract][Full Text] [Related]
12. MEK in cancer and cancer therapy. Neuzillet C; Tijeras-Raballand A; de Mestier L; Cros J; Faivre S; Raymond E Pharmacol Ther; 2014 Feb; 141(2):160-71. PubMed ID: 24121058 [TBL] [Abstract][Full Text] [Related]
13. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. Friday BB; Yu C; Dy GK; Smith PD; Wang L; Thibodeau SN; Adjei AA Cancer Res; 2008 Aug; 68(15):6145-53. PubMed ID: 18676837 [TBL] [Abstract][Full Text] [Related]
14. Targeting BRAF in melanoma: biological and clinical challenges. MandalĂ M; Voit C Crit Rev Oncol Hematol; 2013 Sep; 87(3):239-55. PubMed ID: 23415641 [TBL] [Abstract][Full Text] [Related]
15. ERK inhibition overcomes acquired resistance to MEK inhibitors. Hatzivassiliou G; Liu B; O'Brien C; Spoerke JM; Hoeflich KP; Haverty PM; Soriano R; Forrest WF; Heldens S; Chen H; Toy K; Ha C; Zhou W; Song K; Friedman LS; Amler LC; Hampton GM; Moffat J; Belvin M; Lackner MR Mol Cancer Ther; 2012 May; 11(5):1143-54. PubMed ID: 22402123 [TBL] [Abstract][Full Text] [Related]